<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="4385">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04721444</url>
  </required_header>
  <id_info>
    <org_study_id>5293</org_study_id>
    <nct_id>NCT04721444</nct_id>
  </id_info>
  <brief_title>Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence (COVID-19)</brief_title>
  <acronym>OCTAPUS-AI</acronym>
  <official_title>Optimising Cancer Therapy And Identifying Causes of Pneumonitis USing Artificial Intelligence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Royal Marsden NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Royal Marsden NHS Foundation Trust</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Distinguishing changes on patients that have received thoracic radiotherapy and patients that&#xD;
      are currently receiving or have recently received IO and presenting lung changes which will&#xD;
      be identified using AI.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2021</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Development of a Machine Learning model to distinguish parenchymal lung changes</measure>
    <time_frame>3 years</time_frame>
    <description>The development and validation of an ML/radiomic classifier to distinguish between Infective/COVID-19 pneumonia and cancer therapy induced lung changes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Development of a Machine Learning model to predict recurrence risk after radical radiotherapy for non-small cell lung cancer</measure>
    <time_frame>3 years</time_frame>
    <description>to develop a prognostic AI/radiomic signature for NSCLC recurrence after radical RT (Conventional fractionated RT +/- chemotherapy or stereotactic body RT (SBRT)) to stratify appropriate surveillance and onward care, thus minimising unnecessary hospital visits and resource use.</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Lung Cancer</condition>
  <condition>Covid19</condition>
  <condition>Pneumonitis</condition>
  <arm_group>
    <arm_group_label>Arm A - Cohort A1</arm_group_label>
    <description>Training set: Pneumonitis in the context of IO therapy and negative for infectious pneumonia (including COVID-19)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arms A and B - Cohort B1</arm_group_label>
    <description>Training set B1: IO and RT naive and pneumonia (without COVID-19)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arms A and B - Cohort B2</arm_group_label>
    <description>Training set B2: IO and RT naive and confirmed COVID-19 positive with pneumonia</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Cohort A2</arm_group_label>
    <description>Training set: Pneumonitis in the context of thoracic RT and negative for infectious pneumonia (including COVID-19)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm A - Test Cohort (Cohort C1)</arm_group_label>
    <description>Test set C1: Patients on IO and with possible toxicity versus COVID-19 or other infective pneumonitis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Test Cohort (Cohort C2)</arm_group_label>
    <description>Test set C2: Patients with pneumonitis in context of thoracic RT with possible toxicity versus COVID-19 or other infective pneumonitis.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C</arm_group_label>
    <description>Patients with radiotherapy planning CT scans and post-treatment surveillance CT scans at 3, 6 and 12-months post treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Machine Learning Classification of parenchymal lung change cause</intervention_name>
    <description>Arms A &amp; B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.</description>
    <arm_group_label>Arm A - Cohort A1</arm_group_label>
    <arm_group_label>Arm A - Test Cohort (Cohort C1)</arm_group_label>
    <arm_group_label>Arm B - Cohort A2</arm_group_label>
    <arm_group_label>Arm B - Test Cohort (Cohort C2)</arm_group_label>
    <arm_group_label>Arms A and B - Cohort B1</arm_group_label>
    <arm_group_label>Arms A and B - Cohort B2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Machine Learning Classification of recurrence and non-recurrence</intervention_name>
    <description>Arm C: Radiomics and deep-learning approaches will be used on patient's imaging to develop a risk-signature for recurrence of malignancy following radical treatment</description>
    <arm_group_label>Arm C</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Arms A and B: Adult patients with pneumonitis that have previously been treated with&#xD;
        thoracic radiotherapy or immunotherapy Arm C: Adult patients that have received radical&#xD;
        radiotherapy for NSCLC&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Arms A &amp; B:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
        Cohort A1 (from Arm A) - Immunotherapy (IO) pneumonitis cases: patients currently on or&#xD;
        having received ICI IO in the last 3 months of presentation with:&#xD;
&#xD;
        • New radiological lung changes on CT/CXR (confirmed on report) of a severity and&#xD;
        distribution consistent with IO pneumonitis. These changes should be of severity and&#xD;
        distribution that are not incompatible with viral or lower respiratory tract infection.&#xD;
&#xD;
        AND Must not have had RT involving the thorax (unless this was breast/chest wall RT more&#xD;
        than 5 years ago, which is permissible) AND&#xD;
&#xD;
          -  Where there is documented clinical concern for infection, have undergone one or more&#xD;
             laboratory investigations for viral or lower respiratory tract infection including,&#xD;
             but not limited to Nasopharyngeal aspirate or swab for respiratory virus by PCR;&#xD;
             Sputum sample or bronchial washings MCS with no organism(s) consistent with lower&#xD;
             respiratory tract infection, cytology or beta-glucan/galactomannan for PCP or fungal&#xD;
             infection; broncho-alveolar lavage for markers of infection such as MCS, PCR, fungal&#xD;
             culture, beta-glucan/galactomannan for PCP or evidence of lower respiratory tract&#xD;
             infection (including invasive fungal infection) by cytology, none of which were&#xD;
             considered positive for infection by the clinical team.&#xD;
&#xD;
          -  Where empirical antibiotics were prescribed, patients must either have had a negative&#xD;
             BAL infection screen or may be included at the discretion of the local site PI and&#xD;
             local radiologist with lung interest or two members of the trial management group, one&#xD;
             of whom must be a radiologist with lung interest or respiratory physician or&#xD;
             oncologist with suitable experience of thoracic CT imaging, after after review of the&#xD;
             case-notes.&#xD;
&#xD;
          -  Prophylactic co-trimoxazole prescribed in the context of high-dose steroid therapy is&#xD;
             permitted.&#xD;
&#xD;
        Cohort A2 (from Arm B) - Radiotherapy (RT) pneumonits cases: Patients that have completed a&#xD;
        course of RT involving the thorax (e.g. lung, breast, oesophageal RT) in the last 12 months&#xD;
        prior to presentation, that have not received immunotherapy, with:.&#xD;
&#xD;
        • New radiological lung changes on CT/CXR (confirmed on report) of a severity and&#xD;
        distribution consistent with radiation pneumonitis or early fibrosis (should not include&#xD;
        established fibrosis). These changes should be of severity and distribution that are not&#xD;
        incompatible with viral or lower respiratory tract infection.&#xD;
&#xD;
        AND&#xD;
&#xD;
          -  Where there is documented clinical concern for infection, have undergone one or more&#xD;
             laboratory investigations for viral or lower respiratory tract infection including,&#xD;
             but not limited to Nasopharyngeal aspirate or swab for respiratory virus by PCR;&#xD;
             Sputum sample or bronchial washings MCS with no organism(s) consistent with lower&#xD;
             respiratory tract infection, cytology or beta-glucan/galactomannan for PCP or fungal&#xD;
             infection; broncho-alveolar lavage (BAL) for markers of infection such as MCS, PCR,&#xD;
             fungal culture, beta-glucan/galactomannan for Pneumocystis Pneumonia (PCP) or evidence&#xD;
             of lower respiratory tract infection (including invasive fungal infection) by&#xD;
             cytology, none of which were considered positive for infection by the clinical team.&#xD;
             Where empirical antibiotics were prescribed, patients must either have had a negative&#xD;
             BAL infection screen or may be included at the discretion of the local site PI and&#xD;
             local radiologist with lung interest or two members of the trial management group, one&#xD;
             of whom must be a radiologist with lung interest or respiratory physician or&#xD;
             oncologist with suitable experience of thoracic CT imaging, after review of the&#xD;
             case-notes.&#xD;
&#xD;
          -  Prophylactic co-trimoxazole prescribed in the context of high-dose steroid therapy is&#xD;
             permitted.&#xD;
&#xD;
        B1 (Utilised in Arms A &amp; B) Non-COVID-19 infective cases:&#xD;
&#xD;
          -  New radiological lung changes on CT/CXR (confirmed on report) of a severity and&#xD;
             distribution consistent with lower respiratory tract infection but compatible with the&#xD;
             grade and nature of pneumonitis seen with IO or RT&#xD;
&#xD;
          -  AND&#xD;
&#xD;
          -  Laboratory findings that fulfil one or more of the following criteria of infection:&#xD;
             Nasopharyngeal aspirate or swab positive for a respiratory virus by PCR; Sputum sample&#xD;
             or bronchial washings positive MCS for an organism(s) consistent with lower&#xD;
             respiratory tract infection, cytology or beta-glucan/galactomannan positive for PCP or&#xD;
             fungal infection, positive urine legionella/pneumococcal antigen screen, positive&#xD;
             serology for mycoplasma pneumonia; broncho-alveolar lavage for markers of infection&#xD;
             (MCS, PCR, fungal culture, beta-glucan/galactomannan for PCP or other evidence of&#xD;
             lower respiratory tract infection (including invasive fungal infection) by cytology.&#xD;
             Where no such laboratory findings were positive but the patient improved with&#xD;
             anti-microbial therapy, such cases may be included at the discretion of the local site&#xD;
             PI and local radiologist with lung interest or two members of the trial management&#xD;
             group two members of the trial management group, one of whom must be a radiologist&#xD;
             with a lung interest or respiratory physician or oncologist with suitable experience&#xD;
             of thoracic CT imaging, after review of the case-notes and imaging.&#xD;
&#xD;
          -  Not previously treated with immunotherapy OR&#xD;
&#xD;
          -  Must not have had RT involving the thorax (unless this was breast/chest wall RT more&#xD;
             than 5 years ago, which is permissible)&#xD;
&#xD;
          -  First assessed prior to 1st January 2020 (and therefore not attributable to COVID-19)&#xD;
&#xD;
        B2 (Utilised in Arms A &amp; B) COVID-19 cases:&#xD;
&#xD;
        • Laboratory findings that fulfil one or more of the following criteria of COVID-19&#xD;
        infection: positive COVID-19 PCR test and/or antigen test or other suitable assay that&#xD;
        indicates current infection or previous exposure (including serology tests) as determined&#xD;
        by the trial management group (TMG).&#xD;
&#xD;
        AND&#xD;
&#xD;
          -  New radiological lung changes on CT/CXR (confirmed on report) of a severity and&#xD;
             distribution consistent with COVID-19. These changes should be of severity and&#xD;
             distribution that is not incompatible with the grade of pneumonitis seen with IO or RT&#xD;
&#xD;
          -  Not previously treated with immunotherapy OR&#xD;
&#xD;
          -  Must not have had RT involving the thorax (unless this was breast/chest wall RT more&#xD;
             than 5 years ago, which is permissible)&#xD;
&#xD;
          -  Assessed after 1st January 2020 (and therefore contemporaneous with COVID-19)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        • Patients with documented past medical history of congestive cardiac failure or other&#xD;
        cause for interstitial lung disease&#xD;
&#xD;
        Arm C:&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients (aged 18 or over) treated with radical thoracic RT (conventional&#xD;
             fractionated RT +/- chemotherapy or SBRT) for NSCLC&#xD;
&#xD;
          -  RT planning scan imaging and labelled structure set data available from participating&#xD;
             centre&#xD;
&#xD;
          -  Minimum 2 years of post-RT follow-up data including clinical or histological&#xD;
             confirmation in the case of recurrence and whether the patient is alive as available&#xD;
             from primary care or hospital records.&#xD;
&#xD;
          -  Patients with post-treatment surveillance CT imaging (minimum of first scan&#xD;
             post-treatment and where available +/- further scans within 2 years post-RT, e.g. at&#xD;
             3/6/12 months post-treatment).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any patient that does not have a primary lung mass e.g. Tx disease&#xD;
&#xD;
          -  Any patient being treated for recurrence of a previously treated lung cancer&#xD;
&#xD;
          -  Any patient that did not have radical RT e.g. patients that had high dose palliative&#xD;
             RT&#xD;
&#xD;
          -  Any patient that does not have imaging that meets technical requirements within the&#xD;
             imaging processing and analysis manual&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Richard Lee, MBBS, PhD</last_name>
    <phone>02073528171</phone>
    <email>richard.lee@rmh.nhs.uk</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Bianca Peet</last_name>
    <email>bianca.peet@rmh.nhs.uk</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Guys and St. Thomas' NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shahreen Ahmed</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Imperial College Healthcare NHS Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Danielle Power</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Marsden NHS Foundation Trust</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bianca Peet</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>November 6, 2020</study_first_submitted>
  <study_first_submitted_qc>January 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 22, 2021</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

